SAN DIEGO, CA, Oct. 06, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) SIGYA development-stage company focused on developing therapeutic solutions to address unmet needs in global healthcare announced today that a provisional patent application entitled: “SYSTEM AND METHOD FOR IMPROVING CHEMOTHERAPY DELIVERY AND REDUCING TOXICITY” has been filed with the United States Patent and Trademark Office (“USPTO”).

Cancer is the second leading cause of death in the United States1. Despite therapeutic advances, treatment toxicity, drug resistance, and inadequate delivery to the tumor site limit the usefulness of chemotherapy drugs administered to cancer patients. In particular, it is reported that less than 5% of systemically administered chemotherapy drugs reach their tumor target site2,3. Off-target chemotherapy drugs contribute to treatment toxicity2,3 and may promote the spread of cancer metastases4,5,6,7,8.

To address these challenges, Sigyn’s patent application describes a therapeutic device system whose main goal is to improve chemotherapy and reduce its toxicity. A secondary goal of the therapeutic system is to reduce the dosage of treatment without sacrificing patient benefit, or conversely, increase the dosage of chemotherapy without added toxicity. Along with these goals, the therapeutic system offers the opportunity to reduce drug resistance and inhibit the potential spread of cancer metastases induced by the administration of chemotherapy drugs.

“This patent application is dedicated to friends and family who have died from cancer,” said Jim Joyce, CEO of Sigyn Therapeutics and the inventor of the patent application. “Also, as we continue to develop Sigyn TherapyTM to treat life-threatening conditions that are beyond the reach of drugs, I want to make it clear that the intent of this patent application is to protect the development of a therapeutic system to maximize the benefits of…